Zhi Tong Cai Jing·2025-11-17 14:58Core Viewpoint - The company plans to sell 62% of its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87.19 million, which will enhance asset operational efficiency and provide funding support for business expansion [1] Group 1: Transaction Details - The transaction price for the 62% stake in Taiyuan Pharmaceutical is RMB 87.19 million [1] - After the transaction, Shanxi Tongxiang will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements post-transaction [1] Group 2: Strategic Rationale - The transaction is based on comprehensive considerations for the company's future development [1] - It aims to improve asset operational efficiency and reduce management costs [1] - The company anticipates an increase in profit of approximately RMB 59 million for the year 2025 following the completion of the transaction (unaudited) [1]